No abstract available
MeSH terms
-
Angiogenesis Inhibitors / adverse effects*
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal, Humanized
-
Aptamers, Nucleotide / adverse effects
-
Bevacizumab
-
Ceftazidime / therapeutic use
-
Drug Therapy, Combination
-
Endophthalmitis / drug therapy
-
Endophthalmitis / etiology*
-
Eye Infections / drug therapy
-
Eye Infections / etiology*
-
Humans
-
Intravitreal Injections / adverse effects*
-
Ranibizumab
-
Risk Factors
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / etiology*
-
Vancomycin / therapeutic use
-
Vitreous Body / microbiology
Substances
-
Angiogenesis Inhibitors
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Aptamers, Nucleotide
-
pegaptanib
-
Bevacizumab
-
Vancomycin
-
Ceftazidime
-
Ranibizumab